UPDATE: MiMedx Group (MDXG) Reports Q3 EPS of $0.08, Offers Q4 Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/17/2026
- S&P on track for muted open as Middle East tensions weigh; AI stocks boost Nasdaq
- Trump threatens to bomb Oman over Iran stance
- Why this Wall Street strategist says the "trade is long gold"
- U.S. EV market shows signs of bottoming out: Bernstein
- Micron rises as White House presses Apple to avoid Chinese memory chips
- L3Harris CEO steps down amid conduct review, shares drop
- Reddit leads social media platforms in revenue growth per user
- Northland Upgrades Astera Labs (ALAB) to Outperform, 'Right Time, Customers, and Products'
- Fulcrum Therapeutics to merge with Slate Medicines in all-stock deal
- S&P on track for muted open as Middle East tensions weigh; AI stocks boost Nasdaq
MiMedx Announces Record Results For Third Quarter Of 2017 And Raises Full Year Revenue Guidance
October 26, 2017 2:00 PM EDTMARIETTA, Ga., Oct. 26, 2017 /PRNewswire/ --Â MiMedx Group, Inc. (NASDAQ: MDXG), the leading biopharmaceutical company developing and marketing regenerative and therapeutic biologics utilizing human placental tissue allografts and patent-protected processes for multiple sectors of healthcare, announced today its record results for the third quarter of 2017.
Third Quarter 2017 Financial HighlightsÂ
Q3 2017 revenue of $84.6 million exceeded MiMedx guidance range of $79 to $80 million Q3 2017 revenue grew 31% over Q3 2016 revenue Wound Care revenue of $61.9 million grew 24% over Q3 2016 Surgical, Sports... More